Track topics on Twitter Track topics that are important to you
Cambridge, UK, 20 June 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley will present at this year’s Microbiome Drug Development Summit, 27-29 June in Boston.
Dr Lawley’s talk ‘Culturing the “unculturable” to harness the therapeutic potential of the human intestinal microbiome’ will take place at 9.00am on Wednesday 28 June. The presentation will focus on his pioneering work that allows culturing, genomic and functional characterisation of the majority of the intestinal microbiota.
Microbiotica, which was spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Lawley and is focused on microbiome biology and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics. Cambridge Innovation Capital and IP Group co-invested £8 million into the start-up.
Dr Mike Romanos, CEO of Microbiotica, said: “Over the past decade there has been a groundswell of research demonstrating how pivotal the human microbiome is to health and disease. Trevor’s research at the Sanger Institute has transformed our ability to culture, sequence and characterise bacteria associated with biological phenotypes, opening up new avenues for therapeutic and biomarker discovery, which Microbiotica is translating and commercialising.”
The Microbiome Drug Development Summit is a meeting dedicated to accelerating the discovery, clinical development and commercialisation of a new generation of microbiome-based therapeutics. This year’s event runs from 27-29 June and will be held at Aloft Boston Seaport, Boston.
Notes to Editors
· Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute.
· Microbiotica’s founders are Mike Romanos, Trevor Lawley and Gordon Dougan, FRS.
· CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.
· Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.
About the Microbiome
Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.
For further information please contact:
+44 1223 786063 / +44 7801 480569
Instinctif Partners (for media enquiries):
Sue Charles/Gemma Harris
+44 20 7866 7860NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...